Submit for the Fierce Pharma Marketing Awards - Deadline ends this Friday, July 3rd

breast cancer

Gilead
Pharma

Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC

For now, approval in the PD-L1-positive population makes Trodelvy’s TNBC label broader than its rival. But AZ and Daiichi plan to catch up.
Angus Liu Jun 24, 2026 5:00pm
Green traffic light

FDA approves breast cancer expansion for Pfizer's Ibrance

Jun 24, 2026 2:48pm
Roche
Favicon Fierce Biotech

Roche oral SERD's 1st-line miss spurs new adjuvant trial

Jun 2, 2026 12:45pm
AZ
Favicon Fierce Biotech

FDA delays ruling on AstraZeneca drug after negative adcomm vote

May 27, 2026 4:43am
race car photo finish speed fast

AZ, Daiichi's Datroway approved in first-line TNBC

May 22, 2026 11:32am
Enhertu

Enhertu secures dual FDA approvals in early breast cancer

May 18, 2026 10:52am